Skip to main content

Table 2 Risk of clinical outcomes according to quartiles of sTREM2 in the acute phase of ischemic stroke

From: Soluble TREM2 is associated with death and cardiovascular events after acute ischemic stroke: an observational study from CATIS

  sTREM2, pg/mL p trend
 < 247.45 247.45–401.27 401.27–651.60  ≥ 651.60
Median (pg/mL) 172.16 323.62 503.15 901.40  
The primary outcome: death or cardiovascular events
 No. of cases (%) 56 (6.8) 63 (7.7) 66 (8.0) 103 (12.6)  < 0.001
 Unadjusted HR 1.00 1.13 (0.79–1.61) 1.19 (0.83–1.70) 1.93 (1.40–2.68)  < 0.001
 Multiple-adjusted HR* 1.00 1.01 (0.70–1.46) 1.01 (0.70–1.45) 1.57 (1.11–2.21) 0.002
Death
 No. of cases (%) 32 (3.9) 31 (3.8) 45 (5.5) 78 (9.5)  < 0.001
 Unadjusted HR 1.00 0.97 (0.59–1.59) 1.43 (0.91–2.24) 2.56 (1.69–3.86)  < 0.001
 Multiple-adjusted HR * 1.00 0.76 (0.46–1.25) 1.06 (0.67–1.69) 1.68 (1.09–2.60)  < 0.001
Cardiovascular events
 No. of cases (%) 39 (4.7) 47 (5.7) 40 (4.9) 54 (6.6) 0.19
 Unadjusted HR 1.00 1.21 (0.79–1.85) 1.04 (0.67–1.61) 1.46 (0.97–2.21) 0.09
 Multiple-adjusted HR * 1.00 1.14 (0.74–1.75) 0.97 (0.62–1.52) 1.36 (0.88–2.10) 0.17
Death or severe disability      
 No. of cases (%) 76 (9.4) 97 (12.1) 103 (13.0) 145 (18.6)  < 0.001
 Unadjusted OR 1.00 1.32 (0.96–1.81) 1.43 (1.05–1.96) 2.19 (1.63–2.95)  < 0.001
 Multiple-adjusted OR * 1.00 1.14 (0.80–1.64) 1.09 (0.76–1.56) 1.53 (1.08–2.18) 0.01
Severe disability      
 No. of cases (%) 44 (5.7) 66 (8.5) 58 (7.8) 67 (9.5) 0.01
 Unadjusted OR 1.00 1.55 (1.04–2.30) 1.40 (0.93–2.09) 1.75 (1.18–2.59) 0.02
 Multiple-adjusted OR* 1.00 1.39 (0.90–2.15) 1.10 (0.71–1.72) 1.40 (0.90–2.19) 0.29
  1. sTREM2 soluble triggering receptor expressed on myeloid cells 2, HR hazard ratio, OR odds ratio
  2. * Adjusted for age, sex, current smoking, alcohol drinking, time from onset to randomization, admission NIHSS score, systolic blood pressure, high-sensitivity C-reactive protein, history of hypertension, hyperlipidemia, coronary heart disease, and diabetes mellitus, use of antihypertensive and lipid-lowering medications, family history of stroke, stroke subtype and randomized treatment